Subscribe to receive the latest in aesthetic medicine.
Get breaking developments, expert product comparisons, clinical roundtables, and practice strategies—all for free.
Revance Nears Launch for Botox Rival While AbbVie Sues in ResponseRevance Nears Launch for Botox Rival While AbbVie Sues in Response
Revance Therapeutics has travelled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it faces a new obstacle: a patent lawsuit from drug giant AbbVie.
October 11, 2021
1 Min Read
Press Release: FIERCE Pharma -- AbbVie subsidiary Allergan on Friday sued Revance, alleging the company's proposed frown-line injection Daxibotulinumtoxin A infringes several Botox patents. An FDA decision on Revance's rival drug is "imminent," AbbVie says in the suit, so the pharma giant is seeking a judgment from the court that its patents will be infringed, plus damages that could include a "reasonable royalty and lost profits."
Source: FIERCE Pharma
Feb 15 - Feb 17, 2025
Feb 15 - Feb 17, 2025
AMWC Americas offers evidence-based, cutting-edge scientific content, for all medical aesthetic practitioners. From nonsurgical to minimally invasive treatments, regenerative aesthetics, anti-aging therapies, sexual health, and personalized nutrition, this program covers it all! Plus, you'll gain valuable business and practice management education.
Learn More